Introduction
During the development of new drugs, nonclinical safety studies are carried out in rodent and non-rodent species to identify and characterise adverse effects and facilitate risk assessment for clinical studies. Toxicokinetic (TK) data are an essential component of these studies and are used to correlate circulating drug concentrations (exposure) with pathology or functional effects, the primary endpoints in safety assessment studies. The matrix for determining drug concentration could be blood, plasma or serum.
Exposure-response correlations in animals are subsequently used to define a safe starting dose level in the clinic to set stopping rules and avoid harmful drug accumulation or interactions. Requirements for safety assessment and TK are described in international regulatory guidelines issued by the International Conference on Harmonisation (ICH) [1] . The guidelines indicate that TK information should be obtained to provide proof of drug exposure during the period of dosing but do not dictate how exposure is measured, thereby enabling technological innovations in the bioanalysis of TK samples. TK data are used in a number of ways. For example, it is important to know if there is accumulation over time or if the active drug is clearing differently after repeated drug doses, as might happen with metabolic induction, immunogenic clearance or intoxication of target organs involved in clearance. Exposures are also examined across dose levels to determine whether drug concentrations increase proportionally with the delivered drug dose or if there are irregularities as a result of altered drug absorption or compartmental saturation. Differences in exposure between males and females can also be investigated. All of this information is important for decision making on dosing routes and frequencies in a given patient population.
Individual TK blood samples are typically required at four to six timepoints (within a 24 hour period for small-molecule drugs and over several days for biopharmaceutical drugs) on at least two occasions in each nonclinical safety study (Table 1) . Conventionally, a blood volume of 200 ml has been required to determine circulating drug concentrations. In rodent studies, this relatively large volume of blood could cause anaemia or other secondary effects such as bone marrow and haematological changes, which would confound interpretation of primary drug effects. Therefore, these blood samples are often taken from satellite animals, which are added to the study solely for TK purposes. This can lead to a large increase in the number of rodents required for a typical study. For example, for a typical 4 week repeat oral dose rat study an additional three to nine satellite animals per dose group per sex might be required (depending upon the sample volume and number of timepoints required) in addition to ten main study animals. Further, the use of TK satellite animals means that there is no way to correlate drug levels directly with drug action, because pathology or functional effects are measured in the main study animals and drug exposure is measured in similarly dosed TK satellite animals. The blood, plasma or serum is typically analysed by either LC-MS/MS, or immunoassay to determine levels of drug and, in some cases, associated metabolites, anti-drug antibodies (ADAs) or pharmacodynamic (PD) endpoints. The focus of this paper is on the evaluation of small molecules in rodents because this is where current microsampling efforts are directed and are likely to have the biggest impact. However, the benefits and use of microsampling are not limited to this area. It is often assumed that the rodent is not a relevant model for 'biologic' drugs such as monoclonal antibodies (mAbs), but the screening for potency and use of the rodent for mAbs is on the rise and expected to increase further. Additionally, blood sample volume in rodents and larger species, such as non-human primates, is particularly challenging for biologics because these often require sampling for determination of TK and ADAs as well as monitoring of PD endpoints [ICHS6 (R1)]. The collection of samples for TK analysis using conventional rodent study designs (i.e. with satellite animals) has been identified as the largest influence on rodent numbers used in regulatory toxicology studies [2] . Therefore, microsampling represents the most significant opportunity to reduce rodent use in toxicology studies in the near term. Advances in the sensitivity of bioanalytical techniques, particularly LC-MS/MS, now provide the capability to conduct analysis with much smaller volume samples, around 25-30 ml; these are termed 'microsamples' . A number of the approaches currently in use are illustrated in Fig. 1 [3] [4] [5] [6] . The potential benefits of microsampling are just beginning to be realised in drug development and could have profound effects on regulatory safety assessment studies. This article discusses the barriers to the more widespread adoption of microsampling and outlines the ways forward based on the output from a recent meeting organised by the NC3Rs, an independent scientific organisation that drives innovative technologies to replace, reduce and refine the use of animals in research and safety testing.
Benefits
There are scientific, business and animal welfare benefits to employing microsampling in association with sensitive assay technology. From a scientific perspective, TK sampling from main study animals allows direct correlation of functional and/or pathological changes with concentration of test article in the individual animal's blood. This allows a clear connection between drug exposure and drug action, as is currently the norm in larger preclinical species and human patients but rare in standard rodent studies. Microsampling in all species can also provide scope for the use and characterisation of a broader array of biomarkers, enabling better insight into pharmodynamic effects. The aim is that these endpoints will facilitate better research translation and help to mitigate risks in clinical trials through improved clinical monitoring. From a business perspective, when reduced numbers of satellite animals or none at all are used, less compound and resource (dosing, handling and care) is needed and this can potentially lead to notable cost savings for these studies. There is also significant potential to refine blood sampling procedures across all species to make collection of samples quicker and less stressful for the animal than conventional sampling. In addition to improved welfare, this will deliver better science in that there would be less disturbance to critical physiological parameters (e.g. heart rate and respiratory rate). These wide-ranging incentives have contributed to making microsampling a hot topic of debate within the industry.
The challenge
In May 2013 in central London, the NC3Rs hosted a workshop for 80 delegates from 33 companies and representatives from regulatory bodies to share information and knowledge on the novel microsampling technologies being used and what the barriers were to further implementation. All companies provided information on their current use of, and future plans for, microsampling within drug development through a pre-meeting questionnaire. In identifying barriers to the uptake of microsampling techniques, it was established that there are two primary aspects: (i) functional and clinical pathology evaluation and (ii) approaches to bioanalysis and TK. To date, much of the debate has centred on bioanalytical methods and whether the assay will deliver enough sensitivity with the small samples available and it has been established that many of the bioanalytical issues are surmountable. Much less attention has been given to the real or perceived issues regarding 
All the main study animals are sampled. There are a total of ten animals per sex per group (80 rats). TK profiles are made up from composite samples as follows: six timepoints (#1 to #6), three samples per animal (see x in rows), five samples per timepoint (see x in columns). This gives a total of 30 TK samples per sex per group. Previously 18 samples per sex per group were taken sampling satellite animals (an additional 18 rats).
www.drugdiscoverytoday.com 529 the impact of microsampling on functional and clinical pathological endpoints measured in safety assessment studies in animals. This was identified as the major barrier for uptake of microsampling at the London workshop. There was unanimous opinion among participants towards the rapid implementation of microsampling in nonregulatory and regulatory safety assessment studies in all companies and for robust mechanisms to be put in place to enable this to happen. This article covers current practice in the industry, regulatory experience and the potential future direction of microsampling across drug development.
The current environment
Although there is a lot of anecdotal evidence that suggests companies are using microsampling in drug development, there has been little sharing to date of the current practice.
Information was shared from the participating companies at the workshop through a premeeting questionnaire, posters and speaker presentations. The pre-meeting questionnaire showed that companies use the term 'microsample' for a range of volumes across all species from less than 25 ml to over 100 ml. The definition of a microsample can also differ between species, particularly rodents and non-rodents. The consensus of the meeting was that a microsample should ideally be no more than 50 ml whole blood. Most companies sampled between four and six timepoints per TK profile in individual rodents. Owing to the limited total volume of blood available in the mouse, satellite animals or increased main study group size might still be required for studies in this species when microsampling is employed, but the overall numbers of rodents used can be significantly reduced. From a general perspective, wet blood, plasma and serum microsamples are exactly the same as conventional volume samples of the same matrix, only smaller. We found that, although there is widespread use of microsampling in discovery, dose finding and pharmacokinetic (PK) studies, this is not translated into use in regulatory studies (Fig. 2a) . Only three companies have experience of regulatory acceptance of good laboratory practice (GLP) studies that include microsampling. In total 81% of companies who responded (22/27) are currently using microsampling techniques in drug development and the remaining 19% would like to start to implement them. The majority of companies (17/22) use microsampling for small molecules and the remainder use microsampling for small and large molecules. The most commonly used technique for analysis is small volume plasma, but dried blood spots and small volume blood are also used frequently. Dry plasma spots and small volume serum are less frequently used (Fig. 2b) .
Many companies have used microsampling techniques to sample from satellite animals. By using microsampling rather than conventional sampling the number of satellite mice could be substantially reduced and their use in rat studies potentially eliminated. However, the full scientific potential of microsampling, to relate exposure to toxicological findings in individual animals, is not achieved unless TK samples are obtained from main study animals. Concerns were identified at the workshop that TK sampling from main study animals will affect parameters that are routinely measured in regulatory safety assessment studies, such as clinical pathology, pathology and functional observations on the major organ systems [e.g. on the central nervous system (CNS)] and this was seen as the major barrier to the widespread uptake of microsampling techniques. One piece of data that has been published shows that blood volumes of up to 145 ml collected from rats two days before clinical pathology assessment do not affect the quality of those data but a total of 1250 ml leads to effects on red blood cell parameters, which reflect the loss of blood [4] . Despite these concerns, nearly 50% of companies have used main study animals for microsampling at least once. There is also a question when satellite animals are not included in studies as to whether TK parameters should be generated as full serial profiles from individual animals or as a composite profile from a number of different animals and if control animals should be sampled in an identical manner to those given the drug. 
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FIGURE 1
A selection of different approaches used for microsampling to obtain toxicokinetic samples from rodents in safety assessment studies. (a) Dried blood spots derived from blood collected in a capillary, (b) fixed volume of blood collected in capillary added to fixed volume of water in a tube, (c) hematocrit capillary sealed at one end, centrifuged, scored and broken and plasma obtained in another microcapillary, (d) plasma separation capillary with sealable porous plug, centrifuged and plasma decanted to small tube.
Regulatory experience
The regulatory feedback received at the workshop was that if scientific confidence in the method could be demonstrated then this would feed through to regulatory acceptance. There are limited companies with experience of regulatory submissions but those who have used microsampling in GLP studies have had no issues raised. However, there is still a perception in the industry that there could be regional differences in regulatory viewpoints. All questions that companies have received from regulators have not been related to liquid or preclinical microsampling but have generally been about clinical sampling using Dried Blood Spot (DBS) techniques. Attendees at the workshop identified a number of questions that will probably be addressed at the ICH level later in the year.
Recently an ICH Safety Topic Recommendation working group was set up to 'improve predictivity of nonclinical safety testing by implementation of innovative approaches into regulatory toxicology requirements' . Microsampling has also been identified as a key topic for this group and it is intended that the crosscompany initiative described in this article will provide a valuable evidence base to contribute to this ICH activity.
Future direction of microsampling
Information collected from major pharmaceutical and biotechnology companies and contract research organisations illustrates the widespread interest in, and increasing uptake of, microsampling technologies in drug development. An increase in the use of microsampling for large molecules brings different, additional challenges in bioanalysis. With biologics there is a similar need to relate TK to toxicity outcomes and also to integrate this with an assessment of PD and immunogenicity (ADA formation), all of which require blood samples to be taken. This will be an important area as the biologicals pipeline and investment into biosimilars continue to increase. Although the immediate need for implementation of microsampling is in rodents, the use of microsampling for larger non-rodent species is also likely to increase in the future. This will open up the potential to refine blood sampling procedures, including accessing less-invasive sampling sites, thus improving animal welfare. It will also enable an increase in the number of measured endpoints in blood samples, particularly for biomarkers.
The overall direction of microsampling in the pharmaceutical industry will be towards the use of main study animals to generate TK profiles for GLP safety assessment studies as well as in early discovery and non-GLP studies. The primary hurdle is the limited availability of published data to address whether microsampling from main study animals compromises key toxicological endpoints. The majority of companies attending the workshop had data they were willing to share as part of a larger initiative to generate an evidence base to support the change in practice. The consensus agreed at the workshop was to establish (through the NC3Rs) a framework for data sharing and to publish a consolidated evidence base. This would be used as a basis for discussions with international regulatory bodies.
Whereas immediate benefits on the widespread application of microsampling are likely to be on the reduction and/or removal of satellite animals used to assess PK, TK and PD, meeting attendees identified that blood sampling volumes for clinical pathology are also significant. Currently, these assessments are performed using equipment designed for human clinical sample analysis of relatively large volumes, which in itself impacts the ability to use main study animals for additional assessments. Consequently, there exist opportunities for innovative approaches to reduce blood volumes sampled for clinical pathology especially for those studies in which microsampling might not sufficiently reduce blood sampling burden.
Concluding remarks
There are huge benefits for pharmaceutical, biotechnology and contract research organisations to work together with regulators to improve drug development through the use of microsampling technologies. Microsampling represents a fundamental opportunity to refine blood sampling procedures, substantially reduce animal use in safety assessment studies and enhance scientific and business processes. There is currently interest in this topic at the ICH level. Regulatory clarification alongside change in company practice will support accelerated translation of scientific innovation into regulatory practice. There is a realistic potential to reduce rodent numbers on an individual GLP safety assessment study by almost 50% for mice and rats (Table 2 ). In the future, with the accumulated evidence base, the aim is that the use of mice could be reduced further still, possibly by up to 75% from some current designs. This report provides insight into the current and future direction for microsampling and supports the widespread use of the technology, which is on the verge of shaping the regulatory safety assessment environment of the future. Study design comparison between conventional studies and microsampling studies for rats during drug development. The number of male (M) and female (F) main study animals and satellite animals are shown. The reduction in animal use ranges from 23% to 50% depending on the numbers of satellite animals used and this differs between organisations and studies. Abbreviations: GLP, good laboratory practice; TK, toxicokinetics.
